Clinical Research · global
Can Preoperative Breast Cancer Treatment Use Less Chemotherapy? Antibody Combination Trial Highlights the Importance of Immune Subtyping
Combining two antibody drugs allowed some patients with immune-positive, high-risk early breast cancer to avoid subsequent conventional chemotherapy. But the overall strategy has yet to demonstrate superiority over the control regimen, and lung toxicity reminds researchers that reducing treatment burden must go hand in hand with maintaining efficacy and safety.
For patients with high-risk early breast cancer, treatment before surgery is intended not only to shrink tumors but also to potentially reduce the burden of subsequent drug treatment. A phase 2 trial published in JAMA Oncology on October 22 offers clues about reducing conventional chemotherapy for some patients: start with an immune antibody and an antibody-drug conjugate, then determine whether to add further treatment based on tumor response. However, this strategy has not yet demonstrated superiority over concurrent control treatment.
The I-SPY2.2 randomized trial enrolled 182 patients with high-risk early breast cancer with low or ultralow HER2 (ERBB2) expression. Of these, 105 initially received a combination of rilvegostomig and trastuzumab deruxtecan (T-DXd). The former is a bispecific antibody targeting the PD-1 and TIGIT immune checkpoints; the latter uses an antibody to carry a cytotoxic drug. Avoiding subsequent conventional chemotherapy therefore does not mean that the regimen contains no cytotoxic component.
Tumor immune subtyping was key to the results. A research summary published by JAMA stated that immune-positive disease achieved a pathological complete response rate of 79% across different treatment sequences; this measure means that no residual invasive cancer was found in surgical specimens. Another figure addresses an earlier stage of treatment: according to Targeted Oncology, among patients who initially received the antibody combination, immune-positive tumors had a model-estimated complete response rate of 54% during the initial treatment stage. The two figures cover different treatment scopes and cannot both be interpreted as the efficacy of the antibody combination alone.
The signal for reducing chemotherapy came from patients with immune-positive disease who ultimately achieved a pathological complete response: 21 of them, or 62%, required only the initial antibody combination regimen; 33, or 97%, did not receive anthracycline chemotherapy. The denominators for these percentages are a specific group of patients who had achieved a complete response, and the figures cannot be applied to all trial participants. Immune-negative tumors responded less well, also indicating that low HER2 expression alone is not sufficient to identify patients suited to this strategy.
The trial used a response-adapted treatment design, adding subsequent standard regimens when needed. The ClinicalTrials.gov registration, NCT01042379, lists a trial arm using this antibody combination in block A, followed by standard treatment in block B; that arm is currently closed to enrollment. This design allows researchers to explore who can complete preoperative treatment early, but it also means that the results of the overall strategy cannot be attributed entirely to the initial two drugs.
The potential to reduce treatment still comes with risks. Among the 105 patients who received the antibody combination, 13 developed interstitial lung disease, or 12.4%, including 1 grade 3 event; reports indicated that all reported cases subsequently resolved. Lung toxicity means that whether the regimen reduces the overall burden cannot be measured solely by how much chemotherapy is avoided.
The current evidence supports further research in patients selected through immune subtyping but is not yet sufficient to establish a new routine treatment. Subgroup sizes in this phase 2 trial were limited, and the individual contributions of the two drugs could not be clearly separated. Larger studies are needed to confirm whether reducing chemotherapy can maintain long-term disease control and actually improve patients’ quality of life.